Thursday, July 31, 2025

What Your Nighttime Breathing Says About Your Health

For decades, sleep disturbance was a punch line: the cartoon dad snoring, the disgruntled partner burying their head under a pillow. But science is beginning to paint a less jovial picture. Sleep apnea—a relatively common disorder where breathing repeatedly stops and starts during sleep—is now being taken seriously as a potential biomarker for a host of major health conditions, from cardiovascular disease to Alzheimer’s, even anxiety and depression.

“Sleep is just as important for health as diet and exercise,” says Marishka Brown, director of the US National Center on Sleep Disorders Research. “Poor sleep affects both your mental and physical health; it contributes to cardiovascular disease, increases all-cause mortality, and raises risk factors like obesity, hypertension, and diabetes. And these impacts are independent—they’re not just knock-on effects from something else. Sleep is foundational.”

Obstructive Sleep Apnea (OSA) is one of the most common types of apnea, affecting an estimated 1 billion people worldwide. It occurs when the upper airway repeatedly collapses during sleep, interfering with breathing and lowering oxygen levels. The brain responds by jolting the sleeper awake—sometimes hundreds of times a night—before letting them drift off again, often unaware.

Sufferers may feel exhausted during the day and can experience memory problems. But more than this, the latest research suggests that sleep apnea may play an early and direct role in serious long-term illnesses, especially those affecting the brain.

“Traditionally, sleep apnea was thought of as a disorder that increases with age—especially in men—and leads to heart problems, maybe stroke,” says Bryce Mander, associate professor of psychiatry and human behavior at UC Irvine. “But over the last decade, it’s become clearer that it’s also a risk factor for neurological illnesses like Alzheimer’s and other neurodegenerative diseases.”

Each pause of breath triggered by apnea causes a drop in oxygen levels and a surge in adrenaline for the sleeper. “Over time, that raises the risk of high blood pressure, heart disease, and stroke,” says Atul Malhotra, a sleep medicine specialist and professor at UC San Diego. “There’s strong evidence now that sleep apnea is not just a marker of being unfit. Lean people get sleep apnea too,” he adds.

Hypoxemia—when oxygen levels in the blood are lower than normal—increases inflammation and oxidative stress on cells, explains Mander. “It’s associated with vascular pathology in the brain. So, your blood vessels become damaged, and that can damage the surrounding brain tissue,” he says.

This damage can accelerate the trajectory of a disease like Alzheimer’s or make the brain more vulnerable to it—and researchers now know the effects may appear years before outward symptoms.

A 2015 New York University study found that people with sleep-disordered breathing developed mild cognitive impairment, including Alzheimer’s, up to 10 years earlier than those without. However, those who received treatment for their sleep apnea had the same onset age as those without sleep-disordered breathing.

“Duration of untreated illness is one of the biggest predictors of long-term damage,” says Mander. “The longer you have OSA, the more havoc it can wreak on the body and the brain.”

Notably, the research showed that apnea can manifest differently in REM sleep: “A lot of the memory consolidation and emotional regulation … happens during REM,” Mander explains. “If you’re waking up during REM because of a breathing event, you're fragmenting that process. And if that’s happening night after night for years, it adds up.”

Early diagnosis, therefore, is critical—but it’s currently falling short. Diagnosis frequently relies on a partner noticing loud snoring, an unreliable signal at best.

“The reality is, women—and especially pregnant women—have been overlooked when it comes to sleep disorders,” says Brown. “Right now, our diagnostic standards for sleep apnea are based on a very narrow demographic—typically middle-aged men. But we know that women present differently.”

“What’s classified as ‘mild’ apnea in a man could be moderate or even severe in a woman, particularly during pregnancy,” she adds. “We’ve supported research in pregnant women that found even mild sleep-disordered breathing was an independent risk factor for maternal hypertension, preeclampsia, and gestational diabetes.”

Wearable tech companies are racing to fill the diagnostic gap. Samsung’s Galaxy Watch recently became the first wearable to receive De Novo authorization from the US Food and Drug Administration for detecting signs of OSA. But experts remain cautious. “Wearables and home sleep tests are improving, but they’re not yet a replacement for a full clinical diagnosis,” says Malhotra. “They can give a false sense of security—people see a score and think they’re fine when they’re not.”

Mander is also skeptical: “They’re not accurate enough to replace proper diagnosis,” he says. “They might be better than nothing—as long as you treat them as one piece of information, not the full picture.” While smartwatches and rings can track metrics like heart rate variability, they’re still not reliable at detecting breathing patterns, he adds.

The gold standard in diagnosis is polysomnography, a clinical sleep study that monitors brain waves, oxygen, heart rate, and muscle activity. But this is expensive and time-consuming, and doesn't scale well.

New home-based devices are now offering better options. Mander highlights WatchPAT, which uses finger, wrist, and chest sensors to detect apnea events by analyzing changes in blood vessels. There’s also ARES, a wearable headband monitor that measures airflow, oxygen levels, and sleep position, and NightOwl, a fingertip device that received FDA approval in recent years.

“It's a big step forward, especially for reaching under-served populations who might not be able to access a sleep lab,” Mander says. Still, there are limitations. “Right now, the home test doesn’t know if you’re awake or asleep, much less the sleep stage. It would probably miss people with REM-dominant OSA,” he says. “If we have devices that can detect when these events are happening—in REM versus non-REM—that could help us pick up people earlier and reduce their risk.”

Once diagnosed, CPAP—continuous positive airway pressure—remains the gold standard for treatment, despite being uncomfortable or claustrophobic for some users. It uses a small machine to deliver a steady stream of air through a mask, keeping the airway open during sleep. “CPAP improves symptoms, blood pressure, and we now have emerging evidence that it may reduce cardiovascular risk,” says Malhotra.

For those who can’t tolerate CPAP, new tools such as nasal inserts are emerging on the market. Some interventions are more unconventional—and yet surprisingly effective. “There’s an Australian study that showed learning the didgeridoo helped strengthen throat muscles and reduce OSA severity,” says Mander. “It’s a fun example, but it works.”

Ultimately, the most critical step is awareness. “We used to think snoring was just annoying or funny,” Malhotra says. “Now we understand that it can be a sign of a serious medical condition. If you snore heavily or feel constantly tired, don’t just brush it off—go see your doctor.”

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

Labels: , , , , , , , , , , ,

Tuesday, November 29, 2022

New FDA-Approved Medication Delays Type 1 Diabetes

A preventative therapy for type 1 diabetes called Teplizumab-mzwv recently passed FDA approval and is already on the shelves. It is the first medication capable of delaying the progression of the disease. Listed below are the key facts about the new medication and the way it can benefit type 1 diabetes patients. 
 
How is type 1 diabetes unique? 
Diabetes is an umbrella term for three separate conditions:  
 
Type 1 diabetes - a hereditary autoimmune condition 
 
Type 2 diabetes - the most widespread, may be acquired or inherited  
 
Gestational diabetes - diabetes that appears in pregnancy. 
 
Of these three conditions, type 1 diabetes is the most difficult to treat. While gestational and type 2 diabetes can often be managed with changes in diet, exercise, and a variety of medications, the only available treatment option for type 1 diabetes is insulin.

In type 1 diabetes, the immune system attacks and destroys the cells in the pancreas responsible for producing insulin called beta cells. As a result, the pancreas is able to produce less and less insulin, which makes blood glucose levels rise. Insulin is a hormone produced in the pancreas that allows glucose to enter the cells and be utilized as energy. When the levels of insulin drop, glucose levels skyrocket and eventually damage the body. 
 
Type 1 diabetes is usually diagnosed in children and young adults. A person is at higher risk for type 1 diabetes if they have a relative with type 1 diabetes. This is precisely the group of patients Teplizumab-mzwv can benefit.

How does Teplizumab-mzwv work? 
Teplizumab-mzwv is the first medication capable of delaying the progression of type 1 diabetes. The treatment was approved by the US Food and Drug Administration (FDA) on November 17, 2022, under the brand name Tzield.
Tzield is a synthetic protein that works like a monoclonal antibody produced by the immune system. This is a type of antibody that instructs immune T cells to ignore the beta cells of the pancreas - states ProventionBio, the manufacturer of Teplizumab-mzwv. In addition, the medication urges the immune system to produce more immune cells that protect the beta cells from T cells. 
 
Who can benefit from Teplizumab-mzwv?  
The treatment is designed to slow down the progression of the disease. Therefore, it is beneficial for patients prior to the 3rd stage. Type 1 diabetes is formally divided into three stages that reflect the extent of damage to the beta cells and symptoms. 
 
Stage 1 is asymptomatic. It is characterized by elevated levels of antibodies that attack the pancreas, but blood sugar levels remain normal. Most often, it is diagnosed in children whose parents suffer from diabetes, and it can last for years.

Stage 2 is also asymptomatic, but the patient’s glucose levels start to rise, suggesting a higher degree of beta cell damage. Stage 2 can last from months to years. 
 
Stage 3 is the last. Patients notice symptoms like blurry vision, increased thirst and urination, fatigue, and weight loss. The pancreas can no longer produce enough insulin to sustain the body, and the patient requires supplemental insulin. ​
 
Teplizumab-mzwv is approved for use in all patients with stage 2 type 1 diabetes who are eight or more years old. The medication was shown to delay the advance to stage 3 for more than two years compared to a placebo in a clinical trial. There was some variability among participants, meaning some patients developed stage 3 later and others sooner. 
 
"The drug's potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease," said Dr. John Sharretts of the FDA Center for Drug Evaluation and Research in an official press release of the FDA.

The Medical Trial

Seventy-six participants aged 8-49 years old were involved in the trial. All had stage 2 type 1 diabetes. Forty-four of the participants received IV infusions of teplizumab-mzwv for 14 consecutive days, and the remaining participants got placebo infusions. 
 
After four years and three months, 45% of patients who received teplizumab-mzwv were diagnosed with stage 3 compared to 72% of the placebo group. On average, placebo patients developed stage 3 type 1 diabetes twice as fast as those who got the treatment. 
 
Common side effects of teplizumab-mzwv 
A rash and headaches are the most common side effects of teplizumab-mzwv. Patients who undergo the immunotherapy may be more susceptible to infections because teplizumab-mzwv can temporarily lower the body’s immune protection. 
 
Some patients in the trial developed a temporary decrease in some immune cells. According to ProventionBio, the number of these immune cells started recovering a week after the treatment and fully bounced back a couple of months later.

The manufacturer also cautions that patients who take teplizumab-mzwv should be monitored by a professional due to more serious potential side effects like vomiting or angioedema (swelling under the skin). Sometimes, teplizumab-mzwv triggers something called cytokine release syndrome - an acute syndrome in which T cells cause a systemic inflammatory response that comes with a fever and multiple organ dysfunction. 
 
How much does teplizumab-mzwv cost? 
 
The USA Today reports that a single vial of Teplizumab-mzwv costs $13,850, so the full 14-day treatment is worth $193,000. This is a steep price tag, but many people now have the potential to delay the disease and the burden it creates every day, and for them, teplizumab-mzwv is a life-changer.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

https://GSiyers home remedies.blogspot.com     is my latest addition to my blogs. I'm going to add posts there, do give me your valuable feed back on my blogs. Thanks a lot, take care, be healthy and be happy.

Labels: , , , , , ,